Generation of hepatocyte- and endocrine pancreatic-like cells from human induced endodermal progenitor cells

Rangarajan Sambathkumar, Renate Akkerman, Sumitava Dastidar, Philip Roelandt, Manoj Kumar, Manmohan Bajaj, Ana Rita Mestre Rosa, Nicky Helsen, Veerle Vanslembrouck, Eric Kalo, Satish Khurana, Jos Laureys, Conny Gysemans, Marijke M. Faas, Paul de Vos, Catherine M. Verfaillie

1 KU Leuven, Interdepartmental Stem Cell Institute, Department of Development and Regeneration, Stem Cell Biology and Embryology, Leuven, Belgium, 2 University of Groningen, University Medical Center Groningen (UMCG), Pathology and Medical Biology, Division of Medical Biology, Section Immunoenocrinology, Groningen, The Netherlands, 3 School of Biology, Indian Institute of Science Education and Research, Thiruvananthapuram, Kerala, India, 4 KU Leuven, Department of Clinical and Experimental Medicine, Clinical and Experimental Endocrinology unit, Leuven, Belgium, 5 University of Groningen, University Medical Center Groningen (UMCG), Department of Obstetrics and Gynecology, Groningen, The Netherlands

Abstract

Multipotent Adult Progenitor Cells (MAPCs) are one potential stem cell source to generate functional hepatocytes or β-cells. However, human MAPCs have less plasticity than pluripotent stem cells (PSCs), as their ability to generate endodermal cells is not robust. Here we studied the role of 14 transcription factors (TFs) in reprogramming MAPCs to induced endodermal progenitor cells (iENDO cells), defined as cells that can be long-term expanded and differentiated to both hepatocyte- and endocrine pancreatic-like cells. We demonstrated that 14 TF-iENDO cells can be expanded for at least 20 passages, differentiate spontaneously to hepatocyte-, endocrine pancreatic-, gut tube-like cells as well as endodermal tumor formation when grafted in immunodeficient mice. Furthermore, iENDO cells can be differentiated in vitro into hepatocyte- and endocrine pancreatic-like cells. However, the pluripotency TF OCT4, which is not silenced in iENDO cells, may contribute to the incomplete differentiation to mature cells in vitro and to endodermal tumor formation in vivo. Nevertheless, the studies presented here provide evidence that reprogramming of adult stem cells to an endodermal intermediate progenitor, which can be expanded and differentiate to multiple endodermal cell types, might be a valid alternative for the use of PSCs for creation of endodermal cell types.
Introduction

In the field of regenerative medicine, the creation of functional mature hepatocytes and insulin producing pancreatic β-cells for cell based therapy of liver diseases and diabetes, respectively, are highly sought after goals. Currently, liver failure is treated by whole liver transplantation or transplantation of primary hepatocytes as a bridge to liver transplantation, while for late stage type 1 diabetes, the whole pancreas or cadaveric islet transplantation is the current treatment of choice[1–3]. However, scarcity of donor organs and immunorejection represent a major hurdle to treat most patients. In addition, the pharmaceutical industry is also in need for reliable drug hepatotoxicity screening models, as drug-induced liver injury is one of the most prevalent causes for drug discovery failure[4]. Although primary human hepatocytes are the best source of cells for liver toxicity assessment, scarcity of donor cells, and rapid dedifferentiation of hepatocytes cultured in vitro[5–8] represent major obstacles for these studies.

Human embryonic stem cells (hESCs) and, more recently, induced pluripotent stem cells (iPSCs) are cells that can self-renew long-term and differentiate into cells from the three germ layers[9, 10]. Multiple protocols for in vitro differentiation of pluripotent stem cells (PSCs) to hepatocyte like cells (HLCs)[11–15] and mature β-cells[16–18] have been developed by mimicking in vivo development. Currently, fully mature hepatocytes cannot yet be created from PSCs[19, 20], while recent studies demonstrated that mature functional β-cells can be derived from PSCs[21, 22].

An alternative to create hepatocytes or β-cells from PSCs is the direct transdifferentiation or lineage conversion of, for instance, fibroblasts into these cell lineages using combinations of transcription factors (TFs) and small molecules. Although cells with hepatocyte-like features can be generated[23–25], they are not fully similar to primary human hepatocytes; by contrast, glucose-stimulated insulin producing β-cells have been generated by direct transdifferentiation[26–33]. One drawback of this approach is that transdifferentiation creates post-mitotic cells that cannot be expanded and that repeated transdifferentiations from fibroblasts, which have limited expansion potential, will be required to create new populations of target cells.

Another alternative would be to generate an expandable pool of intermediate endodermal progenitor cells that can, subsequently be differentiated to mature differentiated endodermal cells. In contrast to PSCs, such endodermal progenitors might represent a safer cell source, as differentiation to non-endodermal cells would not occur. Compared to direct lineage conversion, such endodermal progenitors can be extensively expanded[25, 33].

In this study we choose to use human multipotent adult progenitor cells (hMAPCs) for transdifferentiation to expandable endodermal progenitor cells (termed iENDO cells). The rationale for the use of hMAPCs as starting population was threefold: (1) hMAPCs are derived from human bone marrow and can be expanded significantly (for ±70 Population doublings (PDs)) without acquisition of genetic abnormalities[34]; (2) hMAPCs (trade name MultiStem®) are currently being used clinically in the setting of ischemic disorders and as immunomodulators without known toxicity[35–37] (3) although hMAPCs can differentiate in vitro and in vivo in mesodermal cell types, including endothelium, they differentiate, unlike their rodent counterparts, less robust to endodermal cell types[14, 34, 38, 39].

We here demonstrated that using a complement of TFs, chosen based on insights from early endoderm fate specification and differentiation, hMAPCs can be reprogrammed to expandable iENDO cells, which could then be differentiated towards hepatocyte- and pancreatic β-cell-like cells in vitro and in vivo.
Materials and methods

Generation of lentiviral vectors carrying transcription factors

We selected 16 candidate TFs: ESC pluripotency factors (OCT4, SOX2, KLF4, CMYC), TFs expressed in early definitive endoderm (MIXL1, GATA4, SOX17, FOXA1, FOXA2, FOXD3, FOXF1), TFs expressed in late endoderm (HNF4α, HNF6, HNF1α, HEX, CEBPa). Primers were designed with including specific restriction enzyme sites in the flanking regions to amplify the cDNAs (S1 Table). The coding sequence for FOXA2, HNF1α, HNF4α, CEBPα, HNF6, and FOXA1, FOXF1, FOXD3 and for HEX, MIXL1, GATA4, SOX17 were PCR amplified from hESC differentiated to hepatocytes for 12 days, 6 days and 4 days, respectively and cloned into the PLVX-IRES-HYGRO constitutive CMV promoter based lentiviral vector plasmid purchased from (Cat No. 632185, Clontech, Cambridge, USA). Human OCT4, SOX2, KLF4 and CMYC cDNA were excised from pMXs-OCT3/4 (Cat.No. 17217), pMXs-SOX2 (Cat No. 17218), pMXs-KLF4 (Cat No. 17219), pMXs-cMYC (Cat No. 17220) respectively. The cDNAs were cloned into the PLVX lentiviral vector (Addgene, Cambridge, USA). Each TF construct was verified by colony PCR, restriction digestion pattern and cDNA sequence analysis. Each TF containing lentiviral vector was co-transfected with 2nd generation lentiviral packaging (gag pol tat rev)/envelope (VSV-G) plasmids into Lenti-X™ 293T Cell line purchased (Cat No. 632180, Clontech, CA, USA) using Fugene transfection reagent (Cat No. E2311, Promega, Madison, WI, USA). Transfer vector- 6μg, Packaging plasmid (psPAX2) (Cat No. 12260, Addgene, Cambridge, USA)- 3.5μg, Envelope plasmid (pMD2. G) (Cat No. 12259 Addgene, Cambridge, USA)– 1.5μg. Supernatants containing the lentiviral particles were collected after 48hr, filtered through a 0.45μm filter and stored at -80˚C for future use.

Culture conditions for human MAPCs

Human Multipotent Adult Progenitors (hMAPCs) were derived from human bone marrow as described in Roobrouck et al.[34] MAPCs were cultured as previously described[34]. This cells were cultured in medium containing of 60% DMEM low-glucose (Gibco, Invitrogen, Carlsbad, CA, USA), 40% MCDB-201 (Sigma-Aldrich’s Louis, MO, USA), supplemented with 50mM dexamethasone, 10^-4 M L-Ascorbic acid, 1x Insulin-Transferrin-Selenium(TS), 0.5x linoleic acid-bovine serum albumin (LA-BSA)(all from Sigma Aldrich), 1% Penicillin/Streptomycin (Gibco, Invitrogen), along with 2% Serum Supreme (Lonza Biowhittaker, Basel, Switzerland) and human PDGF-BB (R&D Systems, Minneapolis, MN,USA) and human EGF (Sigma-aldrich) (both 10ng/ml). Filter medium through 0.22μm filter (Millipore). Human MAPC-cultures were maintained under hypoxic conditions 37˚C and 5% O2, 5% CO2 humidified incubator at a density of 400 cells/cm2 and were passaged every 2–3 days.

Generation of induced endodermal progenitors (iENDO) from human MAPCs

On day 0, 45,000 hMAPCs cells were plated in 10 cm² petri dishes (Cat No. 150350, Thermo Scientific™ Nunclon™ Delta treated, VWR International, Belgium) in triplicates. On day 1, cells were transduced with a cocktail of 14 or 16 un-concentrated viral vector supernatants (MOI of 3) with infection efficiency (96.57% at 300μl) (S15A and S15B Fig). On day 4, transduced cells were harvested and replated on 1.8% differentiation Matrigel (Cat No. 356231, BD biosciences, Bedford, MA, USA) coated six well plates (Cat No. 3516, Corning-Costar™, MA, USA). A part of the cells was used to evaluate transgene expression. From day 5 onwards, cells were maintained in endoderm induction medium[14] containing 60% DMEM low glucose (Cat No. 31885023, Gibco, Grand Island, NY, USA); 40% MCDB-201 (Cat.No. M6770, Sigma, Saint Paul, MN, USA); 0.5% fetal bovine serum (FBS) (Cat. No. F2043, Sigma, Saint Paul, MN, USA); 0.5x Linoleic acid and 0.08% cholesterol (Sigma, Louis, MO, USA); 1% Penicillin-Streptomycin (Gibco, Invitrogen), 1X ITS (Invitrogen, Carlsbad, CA, USA) and 2% Serum Supreme (Lonza, Basel, Switzerland). The cells were incubated at 37˚C and 5% CO2 for 48 hours and then passaged every 2–3 days.
1x-Penicillin-Streptomycin (10,000 U/mL) (Cat No. 15140122, Gibco, Carlsbad, CA, USA); 0.25x LA-BSA (100x) (Cat No. L9530, Sigma, Saint Louis, MO, USA); 0.25x ITS-A (100x) (Cat No. 51300044, Gibco, Grand Island, NY, USA); 100mL, L-ascorbic Acid (Cat No. A4403, Sigma-Aldrich, Saint Louis, MO, USA); 1µM dexamethasone (Cat. No. D2915, Sigma-Aldrich, Saint Louis, MO, USA), 50µM, 2-mercaptoethanol (50mM) (Cat No. 31350010, Gibco, Grand Island, NY, USA) supplemented with 100ng/ml Activin-A (Cat No. 120-14E), 50ng/ml Wnt3a (Cat No. 315–20) and 5ng/ml BMP4 (Cat No. 120-05ET). All growth factors were purchased from Peprotech, USA. From day 9 to 15 morphological changes from mesenchymal to epithelial cells were assessed by bright field microscopy. Untransduced and PLVX-eGFP empty vector transduced hMAPCs cultured under similar conditions were used as negative control. The iENDO cells were maintained in a 37˚C, 21% O₂, 5% CO₂ incubator. Between days 20–25 transcripts for endogenous mesendoderm/definitive endoderm and late endoderm marker genes were measured by qRT-PCR. Cells were fixed with 4% paraformaldehyde (PFA) (Cat No. P6148, Sigma-Aldrich, Saint Louis, MO, USA) overnight at 4˚C to perform immunostaining.

Expansion potential of iENDO cells

14TF iENDO cells were seeded at one million cells/100 cm² petri dish (Cat No. 150350, Thermo Scientific™ Nunclon™ Delta treated, VWR International, Belgium) coated with 0.1% gelatin. Afterwards every 4–5 days, cells were harvested with 0.25% Trypsin EDTA (Cat No. 25200056, Gibco, Grand island, NY, USA) and enumerated using a NUCLEOCOUNTER NC-100™. Population doublings (PDs) were enumerated as the number of cells initially seeded (C₀) to the number of cells harvested (C₁) at each passage using the following equation: PDnew = PD initial + [log (C₁/C₀)]/log2.

Maintenance and expansion of hESCs

H9 hESCs (purchased from WiCell, Madison, WI, USA) were expanded on a 6 well plate (Cat No. 3516, Corning-Costar®, VWR International, Belgium), in feeder-free conditions on hESC-qualified BD Matrigel™ (Cat No. 354277, BD Biosciences, Bedford, MA, USA) using E8 medium Essential 8™ Basal Medium Essential 8™ Supplement (Cat No. A1517001, Gibco, Grand Island, NY, USA).

Transduction efficiency in hMAPC

To determine the transduction efficiency of hMAPC, we serially diluted the PLVX-IRES-eGFP lentiviral vector (0–1000µl) and transduced an equal number of hMAPC (50,000 cells/well of 12 well plate). After 3 days, we quantified eGFP expression by FACScanto flow cytometer (BD Biosciences). Data were analyzed with FlowJo Sofware (Tree Star, Ashland, OR, USA).

iENDO cell transplantation under kidney capsule of immunodeficient BALBC Rag2<sup>−/−</sup>γc<sup>−/−</sup> mice

Immunodeficient BALBC Rag2<sup>−/−</sup>γc<sup>−/−</sup> mice were maintained in accordance with protocols approved by the ethics committee of KU Leuven. 14 TF iENDO cells were collected from culture dishes by 0.25% trypsin, and injected under the kidney capsule of 10–12-week-old Rag2<sup>−/−</sup>γc<sup>−/−</sup> mice (N = 16). After 3 weeks (N = 3) and 3 months (N = 12), mice were sacrificed, the kidneys harvested and washed with 1X PBS 2–5 times. A small part of the graft was collected in lysis buffer for RNA extraction and qRT-PCR analysis, while the remainder was fixed with 4% PFA overnight at 4˚C for immunohistochemistry and Hematoxyline and Eosin (H&E).
staining. Serum from transplanted and untransplanted mice was collected and stored at -80°C for human albumin and C-peptide analysis.

**Hepatocyte organoid differentiation from 14TF-iENDO cells**

14TF iENDO cells were allowed to form 3D organoids by plating 25,000-iENDO cells/well in low attachment 96 well U bottom cell repellent plates (Cat. No.650970, Greiner-bio one, Belgium) by spinning at 300g for 5 min in Liver Differentiation medium (LDM) consisting of 60% DMEM low glucose; 40% MCDB-201; 1x-Penicillin-Streptomycin; (10,000 U/mL); 0.25x LA-BSA (100x); 0.25x ITS-A (100x); 100mM, L- ascorbic Acid; 1μM dexamethasone; 50μM, 2-mercaptoethanol (50mM) supplemented with in addition as follows, for protocol-A, day 0 to 4: 50 ng/ml aFGF (Cat.No. 100-17A, Peprotech, NJ, USA) with or without 0.6% DMSO (Cat No.D2650 Sigma-Aldrich, Saint Louis, MO, USA) and, subsequently, from day 4 to 20 with 20 ng/ml HGF (Cat No.100-39H, Peprotech, NJ, USA) with or without 2% DMSO. For protocol B, organoids were cultured in 20 ng/ml HGF and 2% DMSO from day 0 to 16. Compacted organoids were maintained in a 37°C, 21% O₂, 5% CO₂ incubator, with medium change every 2 days until day 20 and 16 (protocol-A and B respectively). On the last day of differentiation organoids were collected for qRT-PCR. For immunostaining, organoids were fixed with 4% PFA overnight at 4°C and subsequently, stored in 70% ethanol at 4°C until embedding. Differentiation medium was collected and stored at -80°C for albumin ELISA.

**Hepatocyte organoid differentiation from hESCs**

Differentiation of hESCs to definitive endoderm and hepatocyte-like cells was performed as described previously by our group[40] with addition of 0.6% DMSO between day 0 and day 12 and 2% DMSO between day 12 and day 28. On day 20, cells were washed with 1x PBS (Cat No. 10010015, Gibco, Grand Island, NY, USA), incubated with collagenase-1 (200U/ml, 300 μl for 20 minutes) and detached by pipetting. Cells were collected, spun for 5 minutes at 300g and re-suspended in LDM containing 10% FBS (Cat No. F6178, Sigma-Aldrich, Saint Louis, MO, USA), Revitacell™ (1:100), (Cat No. A2644501, Gibco, Grand Island, NY, USA), 20ng/ml HGF and 2% DMSO. Cells were plated in low attachment round bottom plates at 7000 cells/well in 20μl. After 24hours, compact organoids formed, after which 100μl LDM containing HGF (20ng/ml) and 2% DMSO was added. Subsequently, medium was changed every alternate day. On day 30, medium was collected for albumin ELISA and organoids were harvested for gene expression analysis.

**Pancreatic organoid differentiation from 14TF-iENDO cells**

14TF iENDO cells were allowed to form organoids by plating 25,000-iENDO cells/well in low attachment 96-well U-bottom plates by spinning at 300g for 5 min in pancreatic differentiation medium (PDM) consists of 60% DMEM low glucose; 40% MCDB-201; 1x-Penicillin-Streptomycin; 0.25x LA-BSA; 0.5x ITS-A (100x); 100mM L-ascorbic Acid; 50 μM, 2-mercaptoethanol (50mM) without cytokines. Compacted organoids were formed in 2 days. Subsequently organoids were maintained in pancreatic differentiation basal medium supplemented as described below: Stage-1 (day 0–8): PDM with 1% B27 ℓ; supplement (50x) (Cat No. 17504044, Gibco, Grand Island, NY, USA), 0.1mM Sodium butyrate (Cat No. B5887, Sigma-Aldrich, Saint Louis, MO, USA), 1μM T3 (3,3’,5-triiodo-L-thyronine sodium salt), (Cat No. 64245, Millipore, Calbiochem, San Diego, CA, USA), 3.5mM D-glucose (Cat.No. G7021 Sigma-Aldrich, Saint Louis, MO, USA), 100ng/ml Noggin (Cat No. 120-10C, Peprotech, USA), 5μM ALK5-II Inhibitor (Cat No. ALX-270-445, Enzo life sciences, NY, USA), 5μM SANT-1 (Cat No. 1974, Tocris Biotechnie, Bristol, UK), 10mM nicotinamide (NA), (Cat No. N0636, Sigma-Aldrich, Saint
Louis, MO, USA), and 10μM retinoic acid (RA), (Cat No. R2625, Sigma-Aldrich, Saint Louis, MO, USA); and from day 8–12 also 1μM Trichostatin (TSA) ready-made solution (5mM), (Cat No. T1952, Sigma-Aldrich, Saint Louis, MO, USA). Total glucose concentration in the medium is 10mM. Stage-2 (Day 12–30): RPMI-1640 medium (Cat No. 11875093, Gibco, Grand Island, New York) with 0.05% BSA (Cat No. A9418, Sigma-Aldrich, Saint Louis, MO, USA), 1 μM T3 agonist (Cat No. 64245,Calbiochem, Millipore, CA, USA), 5μM ALK5-II Inhibitor (Cat No.ALX-270-445, Enzo life sciences, NY, USA), 10mM NA (Cat No.N0636, Sigma-aldrich, Saint Louis, MO, USA) and 50ng/ml of IGF-II (Cat No.292-G2, R&D systems, MN, USA). Differentiation medium was changed every other day until day 30 and organoids were maintained in a 37°C, 21% O₂, 5% CO₂ incubator. On day 12 and 30 organoids were collected for qRT-PCR. For immunostaining, organoids were fixed with 4% PFA overnight at 4°C and subsequently, stored in 70% ethanol at 4°C until embedding.

Pancreatic organoid differentiation from hESCs
For hESC differentiation to pancreatic β-cells, we followed the protocol described earlier by our group with minor adaptations [18]. On day 30 cells were harvested for qRT-PCR.

RNA extraction, cDNA synthesis and gene expression
Total RNA was purified using the GenElute™ Mammalian Total RNA Miniprep Kit (Cat No. RTN350, Sigma-Aldrich, Saint Louis, MO, USA) and ZR RNA MicroPrep (Cat No. R1061, Zymo Research, CA, USA). CDNA was generated using 0.5–1μg of RNA with SuperScript® III First-Strand Synthesis SuperMix for qRT-PCR kit (Cat No. 11752050, Invitrogen, CA, USA) and qRT-PCR was performed on a ViiA™ 7 Real-Time PCR System with 384-well plate (Cat No. 4453536, Applied Biosystems, Carlsbad, CA, USA) with a Platinum® SYBR® Green qPCR SuperMix-UDG w/ROX (Cat No. 11744500, Invitrogen, CA, USA) and primers mix at final concentration of 250nM. Gene expression (Cycle threshold) values were normalized based on the PPIG (peptidylprolyl isomerase G) housekeeping gene and the Delta CT calculated. Gene specific primers, purchased from IDT technologies, Leuven, Belgium were designed to distinguish between transgene (CDS-IRES) and endogenous (CDS-3'UTR or Exon-Exon spanning) gene expression. Gene expression graphs or heat maps were represented relative to the housekeeping gene PPIG in log scale. Heat maps were generated using Gene E software (Broad Institute of MIT and Harvard, Cambridge, MA, USA). The efficiency of primers was tested by serial dilution of cDNA and by calculating coefficient of regression (R2). An efficiency of 95-105% with an R2≥ 97% was considered as good (see S2–S5 Tables for list of all qRT-PCR primers used in this study).

Cell viability staining
The LIVE/DEAD® Viability/Cytotoxicity Kit (Cat No. L3224, Molecular probes, Eugene, USA) was used according to the manufacturer recommendations. Stained organoids were observed under inverted fluorescent microscope (Axiovert, Zeiss). Live and dead cells appear as green and red, respectively.

Albumin secretion assay by ELISA
Albumin in culture supernatants and blood of grafted mice were measured using the Human Albumin ELISA Quantitation Set (Cat No.E80-129, Bethyl Laboratories, TX, USA) and the ELISA Starter Accessory Kit (Cat No. E101, Bethyl Laboratories, TX, USA) as per manufacturer’s recommendations. Absorbance was measured at 450nm using Victor 3 plate reader.
(Model No. 1420–041, PerkinElmer, MA, USA). The results obtained were normalized with cell number.

**Human C-peptide ELISA assay**

Secretion of human C-peptide in serum from mice grafted with iENDO cells was analysed using the ultrasensitive human C-peptide ELISA kit (Cat No. 10-1141-01, Mercodia AB, Uppsala, Sweden) as per manufacturer’s recommendations.

**Immunostaining of organoids and in vivo grafts**

14TF iENDO-hepatocyte organoids and iENDO-endocrine pancreatic organoids were fixed with 4% paraformaldehyde (PFA) (Cat No. P6148, Sigma-Aldrich, Saint Louis, MO, USA) overnight at 4°C and subsequently washed with 1X PBS and stored in 70% ethanol at 4°C. For embedding, fixed organoids were encapsulated in 2% agarose gels and stored in 70% ethanol at 4°C until embedding. Fixed iENDO kidney grafts and 3D hepatic and pancreatic organoids were processed using the Excelsior tissue processor and paraffin embedded using the HistoStar (Thermo Scientific). Some paraffin embedded sections were stained with Hematoxyline & Eosin staining. For other sections, immunostaining was performed after melting the paraffin and rehydrating the sections, which were then washed with PBS + 0.2% Triton-X-100 (PBST) for 5 minutes. Following antigen retrieval (Dako Target Retrieval Solution (1x)) sections were permeabilised with 0.2% PBST for 5 minutes. Undifferentiated 14TF iENDO cells cultured on coverslips in 12 well plate were fixed with 4% PFA and permeabilised with 0.2% PBST), blocked with 0.2% PBST + 5% normal donkey serum, and stained overnight at 4°C with primary antibodies and respective isotype controls in Dako diluent. Slides were washed with 1xPBST three times. Immune complexes were detected by incubation with a AlexaFluor AF488 (Green) and AF555 (Red) (1:500) coupled to secondary antibodies for 30 min at room temperature. The nuclei were visualized using Hoechst or DAPI (1:2,000). After 3 washes, slides were mounted with prolong Gold mounting medium. The signals were detected with a Nikon Eclipse Ti-S and Axioimager.Z1 microscope (Carl Zeiss). Identical exposure times were used for isotype and specific antibodies (See S6–S8 Tables, for list of primary, secondary, isotype antibodies). (Note: For cell surface protein CXCR4, stained with anti-human CXCR4 conjugated with PE antibody (1:100), cell permeabilisation and secondary antibody step was not followed).

**hMAPC cell surface maker analysis by flow cytometry**

hMAPC cells were detached with 0.05% trypsin-EDTA and washed with 1xPBS containing 3% FBS. After washing, between 1-2x10⁵ cells were incubated for 20min in the dark at room temperature (RT) with conjugated antibodies or isotype controls (1µg/ml). A list of primary monoclonal antibodies can be found in S9 Table). 7-AAD was used as a marker to exclude dead cells from the analysis. All cells were analyzed on a FACScanto flow cytometer (BD Biosciences) with at least 10,000 recorded events. Data were analyzed with FlowJo Software (Tree Star, Ashland, OR, USA).

**Statistical analysis**

Comparisons between two groups were analysed using an unpaired 2-tailed Student’s t-test. P-values < 0.05(*) < 0.01(**), <0.001(***) were considered significant. Data are shown as mean and error bars represent standard error of mean (SEM) of minimum three independent experiments. All results were analysed using GraphPad prism 6 software.
Results

14TFs can reprogram human MAPCs into induced endodermal progenitor (iENDO) cells

Initially, we transduced human MAPCs with 16 selected TFs, including the pluripotency TFs, OCT4, SOX2, KLF4, CMYC (OKSM) and TFs known to be important in mesendoderm specification (S1A Fig). Cells were maintained in endoderm differentiation medium with Activin-A/Wnt3a/BMP4 on Matrigel coated dishes from day 4 onwards (Fig 1B). On day 4, all TFs were highly expressed except for CEBPα (S1B Fig). Between day 9 and 20, we observed morphological changes from a mesenchymal morphology to clusters of cuboidal cells in the transduced cells, but not in untransduced or PLVX-eGFP transduced cells (S1D Fig).

On day 20 cells were harvested and transcripts for endogenous mesendoderm and as well as definitive and late endodermal marker genes assessed by qRT-PCR and compared with untransduced hMAPC cultured under the same conditions and hESCs differentiated to definitive endoderm cells (day 4) and hepatocyte-/endocrine pancreatic-like cells (day 20). For genes that were part of the pool of transduced TFs, primers were used that only detect endogenous transcripts and not the transduced transcripts (denoted by an “e” in front of the name of the gene (e.g. eGATA6). We found a significant induction of several mesendoderm (S1E Fig), definitive endoderm and epithelial cell marker genes (S1F Fig). Of note, the hepatic endoderm marker genes ALB and AFP (S1G Fig) were also induced, which could be consistent with the known role of FOXA2 and HNF1α, as key regulators of hepatocyte differentiation [23, 41, 42].

Therefore, we repeated the studies without using the FOXA2 and HNF1α viral vectors. Human MAPCs were transduced with 14 TFs (Fig 1A) and maintained as described above (Fig 1B). Between day 9 and 20, we again observed morphological changes from a mesenchymal morphology to clusters of cuboidal cells (Fig 1C). On day 4, all TFs were expressed (S1C Fig). When MAPCs were transduced with only OSKM in endoderm induction medium, clusters of cuboidal cells were observed, which were not expandable and did not express endodermal transcripts (S2A Fig). When OSKM was omitted from the 14TFs no cuboidal cells were observed (S2B Fig).

On day 20, reprogrammed cells were harvested and transcripts for the markers described above assessed by qRT-PCR. We again found significant induction of many mesendoderm, definitive endoderm and epithelial marker genes (Fig 1D and 1E) compared to untransduced MAPC cultured under the same conditions and hESCs differentiated to definitive endoderm cells (day 4) and hepatocyte-/endocrine pancreatic-like cells (day 20). Levels of mesendoderm genes were significantly lower than in day 4 ESC endodermal progeny and levels of definitive endoderm genes approached levels of hESC-endoderm committed cells, and as hoped for, expression of more mature hepatic and pancreatic endoderm genes remained well below levels found in ESC progeny allowed to further mature to hepatocytes and pancreatic endoderm. The endogenous pluripotency genes eOCT4 and NANOG were not activated (data not shown). iENDO cells also stained positive for endodermal markers (CXCR4: 84% ± 9%, SOX17: 90% ± 16%; CK18: 85% ± 15%; (Fig 2B–2D) and respective isotype controls (S2C–S2E Fig). Most importantly, the late hepatic endodermal markers, ALB and AFP were expressed but significantly less higher level when compared with 16TF-iENDO cells (Fig 1F), which was confirmed by immunostaining (S2F–S2H Fig). Also, iENDO cells express tranogene OCT4 at protein level (S2I Fig). We assessed the purity of hMAPCs by cell surface marker expression using flow cytometry (S3A and S3B Fig).

We found hMAPC to be negative for the hematopoietic markers, CD45, CD34, CXCR4, and CD117; the endothelial marker CD31; as well as the CD140a, CD140b, ALP, HLA-class-II, CD271 markers (S3A Fig); and positive for CD44, CD90, CD105, HLA-class 1, CD73, CD146 (S3B Fig). This expression profile is similar to our previous publication [34]. In contrast, in

PLOS ONE | https://doi.org/10.1371/journal.pone.0197046 May 11, 2018 8 / 27
Induced endodermal progenitor cells differentiation to hepatocytes and endocrine pancreatic cells
14TFs iENDO only minimal expression levels of the hMAPC cell surface markers CD 73 and CD105 were detected (S4A and S4B Fig).

14TF iENDO cells can be expanded for at least 20 passages without significant loss of their endodermal progenitor phenotype

The rationale for making iENDO cells, rather than direct reprogramming of somatic cells to mature endodermal cells, was to create an expandable population of cells. Therefore 14TF iENDO cells were passaged in endoderm induction medium with 50ng/ml Activin-A and 25 ng/ml Wnt3a for 6 to 8 passages on Matrigel-coated dishes. In addition we expanded the iENDO cells from passage 6/8 to 20 in a less complex and less expensive medium, namely hMAPC medium on 0.1% gelatin-coated dishes (Fig 2A). We reevaluated expression of the mesendoderm, definitive endoderm, epithelial and late endoderm markers after 6–8 and 15–20 passages. Both after 6–8 and 20 passages, most endogenous transcripts remained unchanged compared to day 20 iENDO cells, even if the definitive endoderm transcripts, SOX17, eFOXA2, CXCR4, CKIT, CXCR4, and eFOXA1, as well as the hepatoblast transcript HNF6 were increased, while eHNF4a decreased (Fig 2E–2G). Importantly, more mature pancreatic and hepatocyte transcripts remained very low. In addition, transcript levels of all transgenes were significantly decreased in 6–8 and 20 passage iENDO cells (Fig 2H). These studies demonstrated that it is possible to create a population of endodermal progenitor cells from hMAPCs that can be expanded at least 20 passages, using a relatively non-expensive medium with a stable transcriptional profile. Genomic stability of early (P4) and late passage (P20) 14TFs iENDO shown that there is no significant genome wide aberrations observed (S5A and S5B Fig).

Grafting of 14TF iENDO cells in vivo

To test their in vivo differentiation capacity, we transplanted one million 14TF ENDO cells (passage 6) under the kidney capsule of BALBC Rag2–/–γc–/– mice in 30μl of PBS (Fig 3A). After grafting, the weight and glucose levels of the mice were regularly assessed. Three mice were sacrificed after 3 weeks (N = 3) and the other (N = 12) were maintained until 3 months after grafting. Unfortunately, of the last group, one mouse died in the 12th week. In all mice, we found that a tumor was formed surrounding the kidney. The tumor was larger at 3 months after transplantation (Fig 3B).

Graft sections were stained with Hematoxylin and Eosin to assess the graft morphology. None of the grafts had invaded into the kidney. In general, at 3 weeks (N = 3) and at 3 months (N = 12), 14TF iENDO cells-derived tumor cells were homogenous containing endodermal cells, akin to a hepatocellular carcinoma (Fig 3C and 3D). However, the graft of the 12 mice sacrificed at 3 months, showed a more heterogeneous morphology, even if most cells still appeared endodermal (Fig 3D).

We immunostained the grafts for the hepatocyte markers AFP, ALB, AAT, HNF4α and the transgene OCT4. Most cells stained positive for OCT4 after 3 weeks (S6A–S6E Fig) (N = 3) and after 3 months (N = 7), cells in the grafts stained positive for the liver markers AFP, ALB.
Induced endodermal progenitor cells differentiation to hepatocytes and endocrine pancreatic cells
and HNF4α, but fewer for AAT (S7A–S7D Fig). In addition, many cells stained positive for OCT4 (S7E Fig). Cells in the graft also stained positive for the intestinal brush-border microvilli marker, VILLIN-C, and the Paneth cell marker, LYSOZYME (S8A Fig), while fewer cells stained positive for the pancreatic endoderm marker PDX1 (S8B Fig). One of the 3-month grafts was morphologically more heterogeneous, and contained fewer AFP, ALB and HNF4α positive cells (S9A–S9D Fig). However, clusters of cells stained positive for the pancreatic endoderm markers PDX1 (S9E Fig and S10A Fig) and NGN3 (S10A Fig), and very few also for SST (S10B Fig). Insulin- or glucagon- positive cells were not detected. In addition, cells in the graft stained positive for the neuroendocrine marker CHGA (S10C Fig), the Paneth cell marker, LYSOZYME (S10D Fig) and the intestinal brush-border microvilli marker, VILLIN-C (S10E Fig). Also, many of the cells still stained positive for OCT4 (S10F Fig). In addition, mesodermal lineage markers, as an example the cardiac specification marker NKX2.5 and ectodermal lineage markers, as an example the neuronal marker β-TUBULIN-III were not observed by immunostaining (S11A and S11B Fig) or by qRT-PCR (S11C and S11D Fig). Control, non-grafted kidney sections did not stain positive for any of these markers.

We also performed qRT-PCR on grafts harvested at 3 weeks (N = 3) and at 3 months (N = 9). At 3 weeks transcript levels for ALB, AFP, AAT and TTR were significantly higher in the graft compared with the initial iENDO cell population, even if mature hepatocyte markers G6PC, NTCP, MRP2 and CYP3A4 were not significantly increased (S12A and S12B Fig). Likewise, after 3 months, transcript levels for ALB, AFP and TTR, but not AAT, G6PC, NTCP, MRP2 and CYP3A4 were significantly increased in the graft compared with the initial cell population (S12A and S12B Fig). Consistent with the immunostaining results, we also detected increased levels of the pancreatic endoderm transcripts PDX1, NGN3, NKX6.1, NEUROD1, PAX4, SST; but not INS or GCG; as well as the gut markers, HNF1β and KRT19, CDX2 in mouse 2 (S12C–S12E Fig). Transcripts for the transgenes were similar before and after grafting, both at 3 weeks and at 3 months (S12F Fig).

We analyzed the mouse serum for presence of human albumin. After 3 weeks, human albumin levels were 1,189 ± 615.44 ng/ml (N = 4), and after 3 months 5,777 ± 7,928 ng/ml (N = 12). In comparison, human blood serum albumine levels are 265,499 ± 12,5354 ng/ml (Fig 3E), while human albumin levels in untransplanted mice were 377 ± 3.28ng/ml. The levels of human albumin depicted are the levels measured minus the levels found in untransplanted mouse serum. Negligible levels of human C-peptide (2.735 ± 0.06 pmol/L) were detected in the blood of (mouse 1&2), 3 months after grafting (Fig 3F), while no c-peptide was detected in the blood of mice 3 months after grafting. c-Peptide levels in human serum were 518.63 ± 584.62 pmol/L.

These studies demonstrate thus that 14TF iENDO cells can differentiate in vivo to multiple endodermal lineages, including hepatoblast, pancreatic endoderm, as well as gut endoderm like cells.
Fig 3. *In vivo* transplantation of 14TF iENDO cells under the kidney capsule forms endodermal tumors but that differentiate into hepatoblasts and pancreatic endocrine like cells. A) Schematic representation of transplantation of undifferentiated iENDO cells under the kidney capsule of RAG2<sup>+/−</sup> γ<sup>−/−</sup> mice. B) Morphology of control kidney (half portion shown) and iENDO cell grafted kidney after three weeks (N = 3) and after three months (N = 12). C) H&E stained sections of iENDO graft. Induced endodermal progenitor cells differentiation to hepatocytes and endocrine pancreatic cells.
14TF iENDO cells can differentiate into hepatocyte-like cells

As spontaneous differentiation occurred from iENDO cells to cells with hepatoblast features in vivo, we assessed if iENDO cells could be directly differentiated in vitro to cells with mature hepatocyte features, using methods developed in the lab for hPSCs[40]. As iENDO cells have an endodermal phenotype, we started differentiation from day 8 (hepatic endoderm specification) or day 12 (hepatoblast maturation) of the hPSC protocol onwards (protocol A vs. B, respectively (Fig 4A and S13A Fig). To determine if there are morphological differences between iENDO derived hepatocyte organoids cultured following protocol-A (day 20) or following protocol-B (day 16) and cultured with or without DMSO, pictures were taken at the end of each protocol. Not many differences were observed between organoids of the two protocols. However, organoids cultured with DMSO appeared smaller than the spheroids cultured without DMSO (Fig 4B and S13B Fig). No DMSO condition cultured organoid core seems to have dead cells compare to the DMSO by H&E Staining (Fig 4B and S13B Fig). An additional variable was addition of DMSO, as others[11, 15, 43, 44] and we have demonstrated that this improved the overall differentiation of PSCs to hepatocyte-like cells (HLCs)[40]. Initial studies demonstrated that the highest transcript levels for \textit{ALB}, \textit{AFP}, \textit{AAT}, \textit{MRP2}, \textit{CYP3A4}, \textit{TTR}, \textit{G6PC}, \textit{eHNF4α} (Fig 4C) were detected when cells were differentiated using protocol A with addition of DMSO compare to the protocol-B (S13C Fig). Therefore, we chose protocol-A + DMSO for further evaluation and comparison with ESCs differentiated as 3D organoids.

Expression levels of \textit{ALB}, \textit{AFP}, \textit{AAT}, \textit{MRP2} and \textit{TTR} transcripts were ±1 log lower than d20 differentiated iENDO compared with day 30 3D ESC-HLCs (differentiated as described [45], until day 20 and as organoids until day 30)(Fig 4C). Transcripts for e\textit{HNF4α}, and e\textit{HNF6}, \textit{CYP3A4} and \textit{G6PC} in 3D iENDO differentiated organoids were comparable with 3D-ESC-HLCs (Fig 4C). Addition of DMSO to either iENDO or hESC differentiation improved differentiation (Fig 4C). Pancreatic endocrine gene transcript levels were not induced under hepatic differentiation conditions (S14A and S14B Fig). When compared to primary human hepatocytes (PHHs), 3D iENDO and 3D hESC hepatocyte-like cells continued to express \textit{AFP}, while transcripts for mature hepatocytes were significantly lower compared with PHHs (Fig 4C). Transgenic \textit{tOCT4} transcripts remained detectable in iENDO-HLCs, albeit at decreased levels compared to undifferentiated iENDO cells (Fig 4C). As negative control, iENDO cells were cultured as organoids without growth factors and small molecules (Fig 4C and S13C Fig), which did not induce increased expression of hepatocyte transcripts.

Immunostaining studies revealed that 3D-iENDO-HLC organoids, differentiated with DMSO, contained 67.86% ± 8.66 \textit{AFP}⁺, 65.32% ± 4.52 \textit{ALB}⁺, and 13.94% ± 0.644 \textit{AAT}⁺ cells. The percentage \textit{AFP}⁺ and \textit{ALB}⁺ cells was significantly higher than in 3D organoids differentiated without DMSO and levels were comparable with hESC-HLC 3D organoids (Fig 4D–4F).

To study the function of iENDO-derived HLCs, we measured albumin secretion by ELISA: supernatants of 3D iENDO-HLCs contained 78.737 ± 8.70 ng/ml ALB (n = 3) in the presence of DMSO and 104.5 ± 61.68 ng/ml without DMSO (n = 3), while supernatants of 3D ESC HLCs cultured with DMSO contained 149.17 ± 9.93 ng/ml ALB (n = 4). Thus levels were similar for 3D iENDO and 3D hESC-HLCs, but significantly lower than in PHHs(Fig 4G).
Thus, consistent with the *in vivo* data, iENDO cells can be guided towards HLCs *in vitro* even though the differentiated cells are less mature than PHHs.

### 14TF iENDO cells can differentiate into pancreatic endocrine cells

We also assessed if 14TF iENDO cells could be differentiated towards endocrine pancreatic cells. 14TF-iENDO cells (passage 6–12) were cultured as organoids with combinations of growth factors and small molecule epigenetic modifiers known to induce endocrine pancreas differentiation as described in (Fig 5A)[18, 21, 22]. We observed compact spheroids as early as 2 days after plating the cells. The morphology of spheroids on day 12 and day 30 of the protocol is shown (Fig 5B). There was not much difference observed between spheroids on day 12 and day 30, except the size of the organoid which was smaller at day 30 than day 12. On day 12, Live/Dead and H&E staining demonstrated that cells in the organoids were viable (Fig 5C and 5D). In parallel, hESCs differentiated into pancreatic endocrine cells by using the protocol described in our group previously[18].

On day 12 (stage 1) and day 30 (stage 2) the expression of pancreatic marker genes was assessed by qRT-PCR (Fig 5E), and compared with undifferentiated 14TF-iENDO cells (day 0), hPSCs differentiated to pancreatic endocrine cells at day 30, and primary human islets. We detected a significant increase in gene expression of *PTF1A*, *PDX1*, *NGN3*, *NKX6.1*, *NEUROD1*, *NKX2.2*, *PAX4*, *MAFA*, *MAFB*, *EHNF6* and *SST* but not for *INS* and *GCG*, nor *NKX6.1* (master regulator β-cells) or *ARX* (master regulator α-cells) (N = 5) (Fig 5E). When compared with hPSC progeny, transcript levels in day 30 iENDO progeny were similar to those of hPSC progeny, except that *INS and GCG*, *ARX*, *PAX6* expression was significantly higher in hPSC progeny. When compared with primary islets, *INS, GCG* and *SST* expression in both iENDO and hESC progeny was significantly lower, whereas endocrine pancreatic genes, including *NGN3*, were significantly higher expressed in iENDO and ESC progeny (Fig 5E). Also, hepatocyte marker transcripts were not induced in iENDO derived pancreatic progeny (S14C and S14D Fig). Following differentiation of iENDO cells, the *OCT4* transgene remained expressed. When iENDO cells were cultured without growth factors and small molecules as organoids, pancreatic transcripts were not induced (Fig 5E).

Day 12 organoids were encapsulated in 2% agarose gel and paraffin embedded sections immunostained for the pancreatic endoderm markers. PDX1 and NGN3 were expressed (Fig 5F and 5G lower image).

Thus, consistent with the *in vivo* data, iENDO cells can be guided towards endocrine pancreatic cells *in vitro*, even though not to mature β- or α-cells.

### Discussion

In this study, we demonstrated that hMAPCs can be reprogrammed into a population of iENDO cells using a combination of 14TFs and culture medium containing Activin-A, Wnt3a and BMP4. iENDO cells can subsequently be expanded for at least 20 passages using a
Induced endodermal progenitor cells differentiation to hepatocytes and endocrine pancreatic cells

**3D Pancreatic endocrine differentiation protocol from IENDO progenitors**

| Stage-1 | Stage-2 |
|---------|---------|
| Day-2   | Day12   |
| DO      | Day30   |
| 1μM Trichostatin-A (TSA) | RPMI 1640 medium, 0.05% BSA, 1 μM T3 agonist, Nicotinamide 10 mM, ALK5i inhibitor 5 μM |

**Pancreatic basal medium, 1% B27 Supplement, 0.1mM Sodium Butyrate 1 μM T3 agonist, Retinoic acid 10 μM, Nicotinamide 10 mM, ALK5i inhibitor 5 μM.**

**Live and dead staining at day 12, stage 1**

**Morphology of pancreatic differentiation organoid**

Day 12  | Day 30

50μm  | 50μm

10X  | 10X

**H&E Staining**

**Relative log**

Row min | Row max

**Expression of genes**

| Genes     | iENDO-DAY 0 | IENDO-PEC Day 12 | hESC-PEC Day 30 |
|-----------|-------------|------------------|-----------------|
| PTF1A     | ++          | +++              | +++             |
| PDX1      | ++          | +++              | +++             |
| NGN3      | ++          | +++              | +++             |
| NKX6.1    | ++          | +++              | +++             |
| NEUROD1   | ++          | +++              | +++             |
| NKX2.2    | ++          | +++              | +++             |
| ARX       | ++          | +++              | +++             |
| PAX4      | ++          | +++              | +++             |
| PAX6      | ++          | +++              | +++             |
| MAFA      | ++          | +++              | +++             |
| MAFB      | ++          | +++              | +++             |
| eHNF6     | ++          | +++              | +++             |
| INS       | ++          | +++              | +++             |
| GCG       | ++          | +++              | +++             |
| SST       | ++          | +++              | +++             |
| tOCT4     | ++          | +++              | +++             |

**Immunofluorescence**

DAPI  | PDX1  | Goat IgG

iENDO  | DAPI  | PDX1  |

iENDO  | DAPI  | Goat IgG

Hoechst | Mouse IgG1 | Mouse IgG1

Hoechst | NGN3 | NGN3

Hoechst | NGN3 | NGN3
relatively inexpensive medium and can differentiate in vivo and in vitro into multiple endodermal cell types.

Reprogramming hMAPCs to iENDO cells was dependent on the presence of OSKM as well as the growth factors Activin-A, Wnt3a and low doses of BMP4. Indeed, removal of either of these components from the reprogramming method failed to induce the generation of epithelialoid clusters and induction of endogenic mesendoderm and definitive endoderm transcripts. This is in line with studies described by Funa S et al. demonstrating that interaction between the TF OCT4, the Nodal effectors SMAD2/3, and Wnt effector β-catenin is required to activate primitive streak gene expression by co-operatively binding to the chromatin upstream of primitive streak gene loci\[46\]. Moreover, Loh et al. demonstrated that low concentrations of BMP4 and Wnt initially specify the anterior primitive streak\[47\], whereas Li et al. found that BMP4 combined with OSKM can activate epithelial markers such as E-CADHERIN, EPCAM, OCLN (OCCULUDIN)\[48\]. Recently, Li et al. and Zhu et al. also demonstrated that definitive endoderm-like cells expressing SOX17 and FOXA2 could be generated from mouse and human fibroblasts by transient overexpression of OSKM combined with a cocktail of epigenetic molecules. These endodermal cells could then subsequently be converted to pancreatic β-cells and hepatocytes, even if knockdown of p53 was required to create the mature progeny from human endodermal cells \[25, 33, 49\].

We also assessed whether, aside from OSKM, the other 10 TFs used in the 14TF used to reprogram hMAPCs to iENDO cells were required. To identify the required complement of TFs for reprogramming MAPCs into iENDO, we removed single TFs from 14 transcription factors and assessing creation of cells with iENDO features. When we removed OCT4, SOX2, KLF4, SOX17, or MIXL1, GATA4, HNF6 from the 14TF pool, the efficiency of iENDO formation decreased, as the resultant cell population did not express the same levels of endogenous definitive endoderm transcripts and the cells could not be expanded (data not shown).

When iENDO cells were grafted under the kidney capsule of immunocompromised mice, we found differentiation solely to endodermal cell, including cells with hepatoblast and endocrine pancreatic characteristics and to a lesser extent cells with intestinal cell characteristics, but not ectodermal or mesodermal positive cells. The reason why, in one mouse assessed at 3 months, iENDO cells differentiated predominantly to hepatoblast-like cells, and in the other mouse, to pancreatic and gut endoderm is currently not clear. However, the iENDO cells formed progressively increasing tumors, which did not invade the kidney. These data are consistent with a study by Seguin et al. wherein SOX17 was overexpressed in hESCs, which lead to the formation of tumors containing both mesodermal and endodermal cell types\[50\]. As is the case of iENDO cells, the SOX17 overexpressing hESCs also still expressed OCT4, which we believe may be responsible for the continued proliferation in vivo. However when Cheng et al. showed that when CXCR4/CKIT enriched endodermal progenitors or human foregut stem cells derived from hPSCs were transplanted in mice, formation of mature endodermal tissues or foregut endodermal cells, respectively, was observed without formation of a tumor\[51, 52\].
In both studies, OCT4 expression was no longer detected in the PSC-derived endodermal progenitor cells that were grafted.

Of note, the hepatoblast-like cells in the iENDO progeny secreted significant amounts of human albumin. When compared with published reports wherein HLCs derived from hESC or hiPSC, albumin levels in the blood of our mice grafted with iENDO cells (±1200 ng/ml after 3 weeks, and >5000 ng/ml after 3 months) appeared to be similar or even higher, except in the mouse wherein the graft had differentiated towards predominantly pancreatic and gut endoderm cells. For instance, Duan et al. reported human albumin levels in the grafted mouse blood of 4–35 ng/ml after 3 weeks[53]; Yusa et al. 40-100ng/ml at 4–5 weeks after grafting; Basma et al. 1000–2000 ng/ml human albumin after 75 days[43]; and Takebe et al., 600-1700ng/ml after 40 days[54]. Albumin levels detected in mice grafted with induced hepatocytes (iHEPs) were reported to be as high as 300 μg/ml in the Du et al. study after 7 weeks[24], but only 400 ng/ml in the Huang et al. study[23]. Differences in the number of cells that secrete albumin in vivo as well as the location of the graft, as well as the mouse model used may impact the results observed. Nevertheless, except for the Du et al. studies, albumin levels detected following grafting of iENDO cells are in line with or higher than published results for HLCs derived from PSCs and iHEPs.

In line with the in vivo data demonstrating that iENDO cells can mature further towards different endodermal lineages, we demonstrated in directed in vitro differentiation studies that iENDO cells can generate hepatocyte-like cells and endocrine pancreatic cells. As iENDO cells already have an endoderm/definitive endoderm phenotype, we omitted the initial commitment step (using Activin-A and Wnt3a) commonly used to differentiate PSCs to endodermal cells towards the pancreatic or hepatocyte lineage.

iENDO progeny expressed significantly higher levels of numerous hepatic genes, to levels near to ±1 log lower compared with hESC progeny. However, as has been described[19, 20], the differentiation system did not induce fully mature hepatocytes, as the iENDO progeny, like hESC-progeny, did not express mature hepatocyte transcripts (such as G6PC and CYP3A4), did not have significant CYP3A4 activity and continued to express high levels of AFP. As has been demonstrated by others[55, 56] and us[40] for hPSC differentiations to HLCs, addition of DMSO increased HLCs differentiation of iENDO cells.

To differentiate iENDO cells towards endocrine pancreatic cells we used a protocol adapted from Pagliuca et al.[21] and Alireza Rezania et al.[22], wherein was demonstrated that mature β-cells can be generated from hPSCs. Although pancreatic endocrine transcripts were induced by the combination of growth factors and small molecules described, and organoid formation, the master regulators for α-cell (ARX and PAX6) and β-cell (NKX6.1) remained very low, and consistent expression of INS and GCG transcripts also remained very low. When compared with hESC differentiation as we described previously[18], we found that iENDO cells differentiated less robustly. hESCs progeny expressed higher levels of the master regulators for α-cells, which was in accordance with higher transcript levels for GCG. Moreover, INS transcripts were significantly higher in hESCs progeny compared with iENDO progeny. A possible explanation for the lower degree of maturation of iENDO-derived progeny compared with hESCs progeny could be the persistent expression of the transgene OCT4 after differentiation. When compared with primary islets, iENDO cells were significantly less mature, with retained expression of NGN3, and have significantly lower levels of INS and GCG transcripts as well as their upstream transcriptional regulators. Of note, NGN3 transcripts in hESCs progeny were also still significantly higher than in mature islets.

In conclusion, we demonstrated that it is possible to reprogram hMAPCs that do not have a robust endodermal differentiation potential to a long-term expandable population of endodermal progenitor cells using TFs and growth factors. These iENDO cells can differentiate both in
vitro and in vivo to multiple different more mature endodermal cell types, even if fully mature hepatocytes and β-cells could not be generated and persistent expression of the pluripotency TF, OCT4, may be responsible, at the same time, for the continued proliferation of the iENDO cells in vivo, and in part for the incomplete maturation of the iENDO cell to mature endoderm cell types. Future studies wherein OCT4 is only transiently expressed may shed light on this. Nevertheless, the current study describes an alternative cell source, which might be a starting point for the creation of mature endodermal cells that could be considered for regenerative medicine and drug studies.

Supporting information

S1 Fig. hMAPC transduced with 16TF results in cells expressing mature hepatocyte markers, not only endodermal markers. A) Selected list of 16 transcription factors. B) Transgene expression analysis by qRT-PCR after 16TF transduction on day 4 C) Transgene expression analysis by qRT-PCR after 14TF transduction on day 4. D) Morphological changes of 14TF transduced hMAPC from day 0 to day 20 after transduction. Untransduced BM-hMAPC and PLVX-eGFP transduced BM hMAPC at day 20 did not show morphological changes (scale bar 100μm). E-G) Relative gene expression (to PPIG, log scale) in day 20 16TF transduced cells represented as a heat-map for mesendoderm (E), definitive endoderm and epithelial marker genes (F) and late endoderm marker genes (G) compared with untransduced hMAPCs and hESC derived endodermal progenitors (day 4) or mature endodermal cells (day 20). All data represent mean of three independent experiments. *p<0.05, **p<0.01 and ***p<0.001 determined by unpaired 2-tailed Student’s t-test.

S2 Fig. Screening of transcription factors for iENDO generation. A) Cuboidal morphology was seen when hMAPC cells were transduced with OSKM alone and endoderm induction medium from day 12 onwards. B) Cuboidal morphological changes were not observed in hMAPC transduced without OSKM (12TFs). C-E) Isotype control staining for CXCR4, SOX17 and CK 18 antibody in hMAPC and iENDO cells. F-H) 14TF iENDO stained for ALB, AFP and AAT with respective isotype controls. I) 14TF iENDO stained for OCT4 with respective isotype control. Representative for 3 independent experiments. Scale bar 100μm.

S3 Fig. Cell surface marker expression of hMAPC by flow cytometry. A) Histograms for surface markers: CD45-FITC, CD34-FITC, CXCR4-PE, CKIT-APC, CD140a-PE, CD140b-PE, CD31-PE, ALP-APC, HLA Class-II-PE, and CD271-PE with respective isotype control. B) Histogram for surface markers: CD44-APC, CD90-FITC, CD105-APC, HLA Class1-APC, CD73-PE, and CD146-PE with respective isotype control. Representative for 3 independent experiments.

S4 Fig. 14TFs iENDO express minimal levels if hMAPC cell surface markers after reprogramming. A-B) Histograms for hMAPC surface markers staining on 14TFs iENDO cells: CD73-PE and CD105-APC with respective isotype control. Representative for 3 independent experiments.

S5 Fig. Genomic stability of 14TFs iENDO early and late passage cells is normal by aCGH array. a) aCGH array on passage 4 14TFs iENDO cells b) aCGH array on passage 20, 14TFs
iENDO cells.

**S6 Fig.** **iENDO cells grafted under the kidney capsule differentiate into hepatocyte like cells after 3 weeks.** A-E) Representative Immunohistochemistry analysis of iENDO derived grafts for AFP, ALB, AAT, HNF4A and OCT4 with respective isotype control staining at 3 weeks after transplantation. Representative for N = 3 independent experiments. Scale bar 50μm.

**S7 Fig.** **iENDO cells grafted under the kidney capsule differentiate into hepatocyte like cells after 3 months.** A-E) Immunohistochemistry analysis of iENDO derived grafts for AFP, ALB, AAT (Scale bar 100μm), HNF4α and OCT4 (Scale bar 50μm), with respective isotype control staining at 3 months after transplantation. Representative for N = 7 independent experiments.

**S8 Fig.** **iENDO cells grafted under the kidney capsule differentiate into pancreatic cells and intestinal like cell types 3 months after transplantation.** A-B) Immunohistochemistry analysis of iENDO derived grafts for intestinal marker Villin-C and Lysozyme and pancreatic endoderm PDX1 with respective isotype control staining at 3 months after transplantation. Representative for N = 7 independent experiments. Scale bar 50μm.

**S9 Fig.** **iENDO cells grafted under the kidney capsule differentiate into cells expressing PDX1 but not hepatoblast proteins in mouse 2, 3 months after transplantation.** A-E) Immunohistochemistry analysis of iENDO derived grafts for AFP, ALB, AAT, HNF4α and PDX1, with their respective isotype control staining at 3 months after transplantation. Scale bar 50μm.

**S10 Fig.** **iENDO cells grafted under the kidney capsule differentiate into pancreatic endocrine and intestinal cell types 3 months after transplantation (mouse 2).** A-E) Immunohistochemistry analysis of iENDO derived graft for PDX1, NGN3, SST, CHGA, LYSOZYME, VILLIN-C, OCT4, with their respective isotype control staining at 3 months after transplantation. Scale bar 50μm.

**S11 Fig.** **iENDO derived tumor grafts do not express mesodermal or ectodermal lineage marker.** A) Cardiac marker NKX2.5 staining on iENDO derived grafts and hESC derived cardiomyocytes. B) Neuronal marker Tubulin-III staining on iENDO derived grafts expressing ALB and HNF4A, and hiPSC derived neurons. C-D) q-RT-PCR analysis for neuronal and cardiac marker in iENDO grafts in comparison with hESC cardiomyocytes and hiPSC neuronal progeny. Relative gene expression (to PPIG, log scale) analysis is represented. Error bars represents standard error of mean of three independent experiments.

**S12 Fig.** **Graft of iENDO cells under kidney capsule express hepatocyte, pancreatic, and gut transcripts (after 3 weeks and 3 months).** A-B) Hepatocyte marker expression, C-D) pancreatic endoderm and endocrine marker expression, E) gut tube marker expression F) transgene expression in transplanted iENDO cells in kidney graft after 3 weeks (N = 3) and after 3 months (N = 9) with comparison with untransplanted kidney and iENDO day 0 or before
transplantation (N = 3). Relative qRT-PCR gene expression relative to the PPIG housekeeping gene in log scale after 3 weeks and 3 months. Error bars represents standard error mean of three independent experiments. *p<0.05, **p<0.01 and ***p<0.001 determined by unpaired 2-tailed Student’s t-test. NS- not significant.

**S13 Fig. Generation of hepatocyte-like cells from iENDO cells in 3D using protocol B.**

A) Protocol time-line for hepatocyte differentiation in 3D from iENDO cells with or without DMSO in protocol B. B) Morphology of iENDO differentiated organoids at day 16 with and without DMSO (N = 3). C) Relative gene expression (to PPIG, log scale) in day 16 iENDO-HLCs ± DMSO represented as a heat-map for hepatocyte markers compared with hESC-HLCs organoids (d30) and PHHs (N = 3). D-F) Immunostaining for AFP, ALB and AAT on day 16 iENDO organoids ± DMSO with their respective isotype control. Scale bar 25 μm (representative example of N = 3). All data represent mean of three independent experiments. *p<0.05, **p<0.01 and ***p<0.001 determined by unpaired 2-tailed Student’s t-test.

**S14 Fig. No expression of pancreatic genes in iENDO-HLC cells and No expression of liver genes in iENDO derived pancreatic endocrine cells.**

A-B) Pancreatic endocrine genes did not express in iENDO differentiated into HLCs method 1 and method 2, with comparison of iENDO differentiated into PEC day 12 and Day 30 (N = 3). C-D) Hepatic endoderm genes were not express in iENDO differentiated into pancreatic progeny, on day 12 and day 30 (N = 3). Relative qRT-PCR gene expression relative to the PPIG housekeeping gene in log scale. Error bars represents standard error mean of three independent experiments. *p<0.05, **p<0.01 and ***p<0.001 determined by unpaired 2-tailed Student’s t-test. NS- not significant.

**S15 Fig. Transduction efficiency of human MAPC.**

A) Histogram plots for different dilutions of PLVX-eGFP viral vector transduced hMAPCs. B) Summary table indicating the percentage of eGFP positive cells obtained by transduction of hMAPC with different dilutions of viral vector. Representative for 3 independent experiments. (Note: Red highlighted 300μl of unconcentrated virus can infect hMAPC at efficiency of 96.57%).

**S1 Table. List of primer sequences used for PCR amplification of cDNA for cloning into PLVX-IRES-HYG lentiviral vector.**

(PDF)

**S2 Table. List of qRT-PCR-primers used for transgene expression analysis (CDS-IRES) based.**

(PDF)

**S3 Table. List of qRT-PCR-primers used for total gene expression analysis (Exon-exon spanning primer).**

(PDF)

**S4 Table. List of qRT-PCR primers used for endogeneous gene expression analysis (CDS-3’UTR or 5’UTR-CDS).**

(PDF)

**S5 Table. List of qRT-PCR primers used for primitive endoderm, mesendoderm, hepatocytes, pancreatic endocrine cells (Exon-exon spanning primers or CDS-3’UTR or
S6 Table. List of primary and secondary antibodies used for immunostaining and immunohistochemistry.
(PDF)

S7 Table. List of primary and secondary antibodies used for immunostaining and immunohistochemistry.
(PDF)

S8 Table. List of isotype antibodies used for immunostaining and immunohistochemistry.
(PDF)

S9 Table. List of FACS antibodies.
(PDF)

Acknowledgments

The authors would like to thank Thomas Vanwelden, Rob Van Rossom, Marc Welters, Hanne Grosemans for their technical help in this project. Additionally, we would like to thank Zhuo-fei Xu for teaching the Gene E software for Heatmap generation in this manuscript and Prof. Dr. Tania Roskams for giving suggestions on tumor grafts staining. The Excelsior and HistoStar were provided by InfraMouse (KU Leuven-VIB) through a Hercules type 3 project (ZW09-03). Additionally, we would like thank Kristel Eggermont and Dr. Robin Duelen for providing hPSCs derived neurons and cardiomyocytes for positive control staining.

Author Contributions

Conceptualization: Rangarajan Sambathkumar, Catherine M. Verfaillie.

Data curation: Rangarajan Sambathkumar, Renate Akkerman, Sumitava Dastidar, Philip Roelandt, Manoj Kumar, Manmohan Bajaj, Ana Rita Mestre Rosa, Nicky Helsen, Veerle Vanslembrouck, Eric Kalo, Satish Khurana.

Formal analysis: Rangarajan Sambathkumar, Renate Akkerman, Sumitava Dastidar, Philip Roelandt, Manoj Kumar, Manmohan Bajaj, Ana Rita Mestre Rosa, Nicky Helsen, Eric Kalo, Satish Khurana.

Funding acquisition: Marijke M. Faas, Paul de Vos, Catherine M. Verfaillie.

Investigation: Rangarajan Sambathkumar, Renate Akkerman, Sumitava Dastidar, Philip Roelandt, Manoj Kumar, Ana Rita Mestre Rosa, Veerle Vanslembrouck, Eric Kalo, Jos Laureys, Conny Gysemans.

Methodology: Rangarajan Sambathkumar, Renate Akkerman, Sumitava Dastidar, Philip Roelandt, Manoj Kumar, Ana Rita Mestre Rosa, Nicky Helsen, Veerle Vanslembrouck, Satish Khurana, Jos Laureys, Conny Gysemans.

Project administration: Marijke M. Faas, Paul de Vos, Catherine M. Verfaillie.

Resources: Catherine M. Verfaillie.

Supervision: Marijke M. Faas, Paul de Vos, Catherine M. Verfaillie.

Validation: Rangarajan Sambathkumar, Renate Akkerman, Ana Rita Mestre Rosa, Veerle Vanslembrouck.
References

1. Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology. 2001; 120(3):749–62. PMID: 11179248.
2. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006; 355(13):1318–30. https://doi.org/10.1056/NEJMoa061267 PMID: 17005949.
3. Naftanel MA, Harlan DM. Pancreatic islet transplantation. PLoS Med. 2004; 1(3):e58; quiz e75. https://doi.org/10.1371/journal.pmed.0010058 PMID: 15630467; PubMed Central PMCID: PMC539048.
4. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003; 349(5):474–85. https://doi.org/10.1056/NEJMra021844 PMID: 12890847.
5. Richert L, Liguori MJ, Abadie C, Heyd B, Mantion G, Halkic N, et al. Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab Dispos. 2006; 34(5):870–9. https://doi.org/10.1124/dmd.105.007708 PMID: 16473918.
6. Rodriguez-Anton C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell JV, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiota. 2002; 32(6):505–20. https://doi.org/10.1080/0049825021012867 PMID: 12160483.
7. Ulvestad M, Bjorquist P, Molden E, Asberg A, Andersson TB. OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture. Biochem Pharmacol. 2011; 82(9):1219–26. https://doi.org/10.1016/j.bcp.2011.07.076 PMID: 21787759.
8. Li AP. Human hepatocytes as an effective alternative experimental system for the evaluation of human drug properties: general concepts and assay procedures. ALTEX. 2008; 25(1):33–42. PMID: 18360726.
9. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282(5391):1145–7. PMID: 9804556.
10. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861–72. https://doi.org/10.1016/j.celrep.2007.11.019 PMID: 18035408.
11. Hay DC, Zhao D, Ross A, Mandalam R, Lebkowski J, Cui W. Direct differentiation of human embryonic stem cells to hepatocyte-like cells exhibiting functional activities. Cloning Stem Cells. 2007; 9(1):51–62. https://doi.org/10.1089/clon.2006.0045 PMID: 17386014.
12. Agarwal S, Holton KL, Lanza R. Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells. 2008; 26(5):1117–27. https://doi.org/10.1634/stemcells.2007-1102 PMID: 18292207.
13. Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology. 2010; 51(1):297–305. https://doi.org/10.1002/hep.23354 PMID: 19998274; PubMed Central PMCID: PMC2946078.
14. Roelandi P, Pauwelyn KA, Sancho-Bru P, Subramanian K, Bose B, Orordova L, et al. Human embryonic and rat adult stem cells with primitive endoderm-like phenotype can be fated to definitive endoderm, and finally hepatocyte-like cells. PLoS One. 2010; 5(8):e12101. https://doi.org/10.1371/journal.pone.0012101 PMID: 20711405; PubMed Central PMCID: PMC2920330.
15. Siller R, Greenhough S, Naumovska E, Sullivan GJ. Small-molecule-driven hepatocyte differentiation of human pluripotent stem cells. Stem Cell Reports. 2015; 4(5):939–52. https://doi.org/10.1016/j.stemcr.2015.04.001 PMID: 25937370; PubMed Central PMCID: PMC4437467.
16. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol. 2008; 26(4):443–52. https://doi.org/10.1038/nbt1393 PMID: 18288110.
17. D’Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006; 24 (11):1392–401. https://doi.org/10.1038/nbt1259 PMID: 17053790.
Induced endodermal progenitor cells differentiation to hepatocytes and endocrine pancreatic cells

18. Cai Q, Bonfanti P, Sambathkumar R, Vanuytsel K, Vanhove J, Gysemans C, et al. Prospectively isolated NGN3-expressing progenitors from human embryonic stem cells give rise to pancreatic endocrine cells. Stem Cells Transl Med. 2014; 3(4):489–99. https://doi.org/10.5966/stcm.2013-0078 PMID: 24493654; PubMed Central PMCID: PMCPMC3973709.

19. Baxter M, Withey S, Harrison S, Segeritz CP, Zhang F, Atkinson-Dell R, et al. Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. J Hepatol. 2015; 62(3):581–9. https://doi.org/10.1016/j.jhep.2014.10.016 PMID: 25457200; PubMed Central PMCID: PMCPMC434496.

20. Godoy P, Schmidt-Heck W, Natarajan K, Lucendo-Villarin B, Szolkinicka D, Asplund A, et al. Gene networks and transcription factor motifs defining the differentiation of stem cells into hepatocyte-like cells. J Hepatol. 2015; 63(4):934–42. https://doi.org/10.1016/j.jhep.2015.05.013 PMID: 26022688; PubMed Central PMCID: PMCPMC4580233.

21. Pagliuca FW, Millman JR, Gurtler M, Segel M, Van Dervort A, Ryu JH, et al. Generation of functional human pancreatic beta-like cells in vitro. Cell. 2014; 158(2):428–39. https://doi.org/10.1016/j.cell.2014.09.040 PMID: 25303955; PubMed Central PMCID: PMCPMC4617632.

22. Rezania A, Bruin JE, Arora P, Rubin A, Batashansky I, Asadi A, et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014; 32(11):1121–33. https://doi.org/10.1038/nbt.3033 PMID: 25211370.

23. Huang P, Zhang L, Gao Y, He Z, Yao D, Wu Z, et al. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell. 2014; 14(3):370–84. https://doi.org/10.1016/j.stem.2014.01.003 PMID: 24589297.

24. Du Y, Wang J, Jia J, Song N, Xiang C, Xu J, et al. Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell. 2014; 14(3):394–403. https://doi.org/10.1016/j.stem.2014.01.006 PMID: 24589296.

25. Zhu S, Rezvani M, Harbell J, Mattis AN, Wolfe AR, Benet LZ, et al. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature. 2014; 508(7504):59–7. https://doi.org/10.1038/nature13026 PMID: 24572354; PubMed Central PMCID: PMCPMC4161230.

26. Pennarossa G, Maffei S, Campagnoli M, Tarantini L, Gandolfi F, Breveni TA. Brief demethylation step allows the conversion of adult human skin fibroblasts into insulin-secreting cells. Proc Natl Acad Sci U S A. 2013; 110(22):8945–53. https://doi.org/10.1073/pnas.1220637110 PMID: 23696663; PubMed Central PMCID: PMCPMC3760074.

27. Katz LS, Gersh-Raaka E, Gershengorn MC. Reprogramming adult human dermal fibroblasts to islet-like cells by epigenetic modification coupled to transcription factor modulation. Stem Cells Dev. 2013; 22(18):2551–60. https://doi.org/10.1089/scd.2013.0134 PMID: 23627894; PubMed Central PMCID: PMCPMC3760074.

28. Lee J, Sugiyama T, Liu Y, Wang J, Gu X, Lei J, et al. Expansion and conversion of human pancreatic ductal cells into insulin-secreting endocrine cells. Elife. 2013; 2:e00940. https://doi.org/10.7554/eLife.00940 PMID: 24258277; PubMed Central PMCID: PMCPMC3826580.

29. Salzman M, Gupta S, Giri RK, Berkovich I, Sappal BS, Karnieli O, et al. Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells. Proc Natl Acad Sci U S A. 2003; 100(12):7253–8. https://doi.org/10.1073/pnas.1136854100 PMID: 12756298; PubMed Central PMCID: PMCPMC165862.

30. Salzman M, Anker-Kitai L, Efrat S. Differentiation of human liver-derived, insulin-producing cells toward the beta-cell phenotype. Diabetes. 2005; 54(9):2568–75. PMID: 16123344.

31. Chen YJ, Finkbeiner SR, Weinblatt D, Emmett MJ, Tameire F, Yousefi M, et al. De novo formation of insulin-producing “neo-beta cell islets” from intestinal crypts. Cell Rep. 2014; 6(6):1046–58. https://doi.org/10.1016/j.celrep.2014.02.013 PMID: 24613355; PubMed Central PMCID: PMCPMC4245054.

32. Mauda-Havakuk M, Litchev E, Nemchinovski N, Nemchinovski E, Nakar O, Winkler E, Mazkereth R, et al. Ectopic PDX-1 expression directly reprograms human keratinocytes along pancreatic insulin-producing cells fate. PLoS One. 2011; 6(10):e26298. https://doi.org/10.1371/journal.pone.0026298 PMID: 22028850; PubMed Central PMCID: PMCPMC3196540.

33. Zhu S, Russ HA, Wang X, Zhang M, Ma T, Xu T, et al. Human pancreatic beta-like cells converted from fibroblasts. Nat Commun. 2016; 7:10080. https://doi.org/10.1038/ncomms10080 PMID: 26733021; PubMed Central PMCID: PMCPMC4729817.

34. Roobrouck VD, Clavel C, Jacobs SA, Ulloa-Montoya F, Crippa S, Sohni A, et al. Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells. 2011; 29(5):871–82. https://doi.org/10.1002/stem.21433224.

35. Jacobs SA, Pinxteren J, Roobrouck VD, Luyckx A, van’t Hof W, Deans R, et al. Human multipotent adult progenitor cells are nonimmunogenic and exert potent immunomodulatory effects on alloreactive
T-cell responses. Cell Transplant. 2013; 22(10):1915–28. https://doi.org/10.3727/096368912X657369 PMID: 23031260.

36. Jacobs SA, Roobrouck VD, Verfaillie CM, Van Gool SW. Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunal Cell Biol. 2013; 91(1):32–9. https://doi.org/10.1038/icb.2012.64 PMID: 23295415; PubMed Central PMCID: PMCPMC3540326.

37. Mora-Lee S, Sirerol-Piquer MS, Gutierrez-Perez M, Gomez-Pinedo U, Roobrouck VD, Lopez T, et al. Therapeutic effects of hMAPC and hMSC transplantation after stroke in mice. PLoS One. 2012; 7(8): e43683. https://doi.org/10.1371/journal.pone.0043683 PMID: 22952736; PubMed Central PMCID: PMCPMC3432058.

38. Aranguren XL, Luttun A, Clavel C, Moreno C, Abizanda G, Barajas MA, et al. In vitro and in vivo arterial differentiation of human multipotent adult progenitor cells. Blood. 2007; 109(6):2634–42. https://doi.org/10.1182/blood-2006-06-030411 PMID: 17090652.

39. Kumar A, Lo Nigro A, Gysemans C, Cai Q, Esquerra C, Nelson-Holte M, et al. Reversal of hyperglycemia by insulin-secreting rat bone marrow- and blastocyst-derived hypoblast stem cell-like cells. PLoS One. 2012; 7(8): e43683. https://doi.org/10.1371/journal.pone.0043683 PMID: 22952736; PubMed Central PMCID: PMCPMC3432058.

40. Chetty S, Pagliuca FW, Honore C, Kweudujeu A, Rezania A, Melton DA. A simple tool to improve pluripotent stem cell differentiation. Nat Methods. 2013; 10(6):553–6. https://doi.org/10.1038/nmeth.2442 PMID: 23584186; PubMed Central PMCID: PMCPMC3694177.

41. Subramanian K, Owens DJ, Raju R, Firpo M, O'Brien TD, Verfaillie CM, et al. Spheroid culture for enhanced differentiation of human embryonic stem cell-derived hepatocytes. Gastroenterology. 2009; 136(3):990–9. https://doi.org/10.1053/j.gastro.2008.10.047 PMID: 19026649; PubMed Central PMCID: PMCPMC2732349.

42. Li W, Li K, Wei W, Ding S. Chemical approaches to stem cell biology and therapies. Cell Stem Cell. 2013; 13(3):270–83. https://doi.org/10.1016/j.stem.2013.08.002 PMID: 24012368; PubMed Central PMCID: PMCPMC3898630.

43. Cheng X, Ying L, Lu L, Galvao AM, Mills JA, Lin HC, et al. Self-renewing endodermal progenitor lines generated from human pluripotent stem cells. Cell Stem Cell. 2012; 10(4):371–84. https://doi.org/10.1016/j.stem.2012.02.024 PMID: 22482503; PubMed Central PMCID: PMCPMC3580854.
53. Duan Y, Catana A, Meng Y, Yamamoto N, He S, Gupta S, et al. Differentiation and enrichment of hepatocyte-like cells from human embryonic stem cells in vitro and in vivo. Stem Cells. 2007; 25(12):3058–68. https://doi.org/10.1634/stemcells.2007-0291 PMID: 17885076.

54. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013; 499(7459):481–4. https://doi.org/10.1038/nature12271 PMID: 23823721.

55. Hay DC, Zhao D, Fletcher J, Hewitt ZA, McLean D, Urruticoechea-Uriguen A, et al. Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells. 2008; 26(4):894–902. https://doi.org/10.1634/stemcells.2007-0718 PMID: 18238852.

56. Ulvestad M, Nordell P, Asplund A, Rehnstrom M, Jacobsson S, Holmgren G, et al. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochem Pharmacol. 2013; 86(5):691–702. https://doi.org/10.1016/j.bcp.2013.06.029 PMID: 23856292.